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I read with interest the recent paper by Ramanathan et al., 1 that compared outcomes among neonates treated with different animal-derived surfactants. The authors' conclusion that poractant alfa may offer a survival advantage over calfactant or beractant contradicts everything we understand about the biology of natural surfactants, and virtually all prospective clinical data we have gathered for the past 30 years. They base their conclusion on a retrospective review using a limited administrative data set, an approach with inherent weaknesses that makes such a paradigmshifting claim untenable.
Their claim is not entirely new. The authors have previously published abstracts of portions of this data set, and presented their findings at a variety of forums since 2007. What is particularly concerning is that in the present article the authors have omitted important information previously presented that would underscore some of the weaknesses of the present study. Specifically,
(1) In a previous abstract that reported from the same data source from January 2003 through June 2006 (overlapping the present report's data set by 2 years) the authors note that nearly 60% of the cases were omitted due to incomplete data.
2
Omitting such a large number of cases precludes any reliable conclusions. In the present study the authors do not state how many cases were omitted. (2) In a previous but separate abstract that reported from the same data source as above, the authors found that neonatal intensive care unit and hospital lengths of stay (LOS) were significantly lower in poractant alfa-treated infants than in either beractant-or calfactant-treated infants.
3 Shorter LOS coupled with lower mortality suggests that poractant alfatreated infants were significantly more mature, less ill or both. This is consistent with a large retrospective database analysis published earlier this year 4 (although not cited by the authors in the present study). (3) In the present study, the authors do not report LOS and do not case-adjust for LOS in any of their analyses. Although they attempt to adjust for case mix and mortality risk by All Patient Refined Diagnosis Related Groups this approach has not been validated for this type of study, particularly when a large percentage of the cases are omitted due to incomplete data.
There are significant pitfalls when using an administrative database to conduct clinical research that the authors do not adequately address. Although they did correctly note that retrospective analyses are subject to significant bias and error, they failed to take steps often found in retrospective studies to reduce these risks. Specifically, there was no attempt to obtain missing data or even verify the data that were included. Although the authors cited several articles that they believed are consistent with their findings, these are primarily limited to those studies showing no clinical differences between calfactant and beractant. Although they stated in their paper that the results of their study 'should be interpreted and validated in the context of other evidence from the medical literature', they were unable to do so because there is simply no literature supporting a mortality difference between natural surfactants, as noted in a previous review 5 (that the authors also failed to cite in their paper). Moreover, the authors omitted reference to the largest retrospective study to date comparing outcomes by natural surfactant preparation that failed to show any differences in mortality. 4 The authors' speculation about the reason for outcome differences between surfactants also conflicts with the body of evidence from animal and clinical studies. They suggest that different doses of phospholipid may explain differences in outcome, although the phospholipid content in all commercially available products far exceeds the lung's normal phospholipid pool size, 6 and has not been demonstrated to affect outcome in large randomized clinical trials. Instead, the authors cited their own previous small trial in which a post hoc subgroup analysis suggested that a 200 mg kg À1 dose of poractant alfa was associated with lower mortality than 100 mg kg À1 doses of either poractant alfa or beractant in preterm infants at 36 weeks postconceptional age (P ¼ 0.05).
7 This finding is inconsistent with all other outcomes reported in their study, including survival at 28 days and survival without chronic lung disease, which did not differ among groups in either the overall or the subgroup analyses. It also conflicts with data from an earlier randomized prospective trial that included >10-fold greater numbers of poractant-treated infants, and which found no differences in any clinically important outcomes, including mortality, between infants treated with 200 mg kg À1 poractant alfa and infants treated with 100 mg kg À1 .
8
However, the authors did not discuss this important study in their present report.
Given the inherent weaknesses in this type of retrospective study, the omission of a significant number of cases as well as important covariates in the analysis, and the weight of previously published data relevant to this important clinical question, the authors should exert extreme caution in interpreting their findings. In a recent review on this precise topic, I concluded 'there is no valid evidence for a mortality benefit of one surfactant preparation over another '. 5 This study by Ramanathan et al. has not altered my assessment.
We would like to thank Dr Cummings for giving us the opportunity to explain our study results. Results from nine randomized, controlled, trials (RCTs), 1-9 including the one that has been just published (e-pub ahead of print) by Dizdar et al.
9 and meta-analyses 10-12 comparing animal-derived surfactants, namely, poractant alfa (PA), beractant (BE), bovactant (BO) and/or calfactant (CA), have consistently shown faster weaning of oxygen and mean airway pressure, less need for redosing, fewer days on oxygen and mechanical ventilation, shorter length of stay (LOS) as well as survival advantage in babies treated with PA. These advantages with PA over BE, CA or BO are likely related to major biological and/or biochemical differences between these animal-derived surfactant preparations. PA contains the highest amount of phospholipids when compared with BE or CA. Higher amount of phospholipids has been shown to downregulate oxidative functions in monocytes and confer better anti-inflammatory properties. 13 In addition, bacterial growth in different surfactant preparations is influenced by microbial species and the composition and dose of the surfactant. PA was bactericidal in a dose-dependent fashion and differed from BE and BO, a surfactant preparation similar to CA.
14 PA contains the highest amount of plasmalogens (PL) when compared with BE.
15 BO contains the lowest amount of PL.
15 PL are anti-oxidant phospholipids and presence of higher amounts of PL in the tracheal aspirates from pre-term infants has been shown to be associated with a lower risk for bronchopulmonary dysplasia (BPD).
16 Also, the amount of surfactant-associated protein B (SP-B) is highest in PA when compared with BE or CA. SP-B is the most important SP in helping the phospholipids to rapidly adsorb at the air-liquid interphase and in decreasing surface tension. Furthermore, the phospholipid molecular species of PA is much closer to that of human surfactant. 17, 18 In our paper, 19 we have clearly acknowledged the limitations of the retrospective study and took steps to minimize any shortcomings. The major finding of lower mortality in PA-treated infants is consistent with results from previously published small RCTs as well as meta-analyses comparing PA and BE. None of the studies comparing BE with CA have shown any differences in the need for redosing, days on oxygen or mechanical ventilation, BPD or mortality. Interestingly, Bloom et al.
1 reported a higher mortality rate in infants with a birth weight <600 g treated with CA
